Triacelluvax
diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)
Table of contents
Overview
The marketing authorisation for Triacelluvax has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Triacelluvax
|
| Agency product number |
EMEA/H/C/000181
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
J07AJ
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Chiron S.p.A.
|
| Revision |
0
|
| Date of issue of marketing authorisation valid throughout the European Union |
11/01/1999
|
| Contact address |
CHIRON S.p.A.,
Via Fiorentina 1, 53100, Siena Italy |
Product information
28/01/2002 Triacelluvax - EMEA/H/C/000181 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
TRIACELLUVAX is indicated for active immunisation of children from 6 weeks up to 7 years of age against diphtheria, tetanus and pertussis.